MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.84

+0.8%

3:26 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	12/1/2006 3:55:41 PM
	of 2240

Genmab Up 5.9% On Takeover Talk >GEN.KO Friday, December 01, 2006 7:52:45 AM ET Dow Jones Newswires 1138 GMT [Dow Jones] Genmab (GEN.KO) trades +5.9% at DKK287.50 on talk it is subject to a DKK400 per share takeover target. Code Securities analyst Samir Devani says Genmab is a quite attractive asset and may have encountered a potential buyer during ongoing partnership discussions for its HuMax-CD20 project. He says it would be attractive to many pharmaceuticals considering HuMax-CD20 is one of the biggest biotech pipeline projects in Europe. He mentions Roche (RHHBY) as a potential buyer, considering it already collaborates with the company. Has hold recommendation on the share. Genmab wasn't immediately available for a comment. (MKR)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next